About Seres Therapeutics, Inc.
https://www.serestherapeutics.comSeres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
CEO
Thomas J. DesRosier
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-22 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FLAGSHIP VENTURES FUND IV, L.P.
Shares:14.08M
Value:$226.46M
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
Shares:12.68M
Value:$203.94M
BLACKROCK INC.
Shares:1.76M
Value:$28.34M
Summary
Showing Top 3 of 60
About Seres Therapeutics, Inc.
https://www.serestherapeutics.comSeres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $351K ▲ | $9.48M ▼ | $8.2M ▲ | 2.34K% ▲ | $0.94 ▲ | $9.26M ▲ |
| Q2-2025 | $0 | $23.82M ▲ | $-19.86M ▼ | 0% | $-2.27 ▼ | $-18.8M ▼ |
| Q1-2025 | $0 | $23.71M ▼ | $32.68M ▲ | 0% | $3.76 ▲ | $33.76M ▲ |
| Q4-2024 | $0 | $28.84M ▼ | $-15.64M ▼ | 0% | $-1.81 ▲ | $-14.55M ▲ |
| Q3-2024 | $0 | $29.17M | $88.78M | 0% | $-7.59 | $-49.63M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.64M ▲ | $143.47M ▼ | $99.78M ▼ | $43.7M ▲ |
| Q2-2025 | $45.38M ▼ | $143.8M ▼ | $110.85M ▼ | $32.95M ▼ |
| Q1-2025 | $58.85M ▲ | $164.18M ▲ | $113.72M ▼ | $50.47M ▲ |
| Q4-2024 | $30.79M ▼ | $139.81M ▼ | $126.03M ▼ | $13.78M ▼ |
| Q3-2024 | $66.82M | $178.74M | $154.82M | $23.92M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.2M ▲ | $2.21M ▲ | $-8K ▲ | $61K ▲ | $2.26M ▲ | $2.2M ▲ |
| Q2-2025 | $-19.86M ▼ | $-13.29M ▼ | $-181K ▼ | $0 ▼ | $-13.47M ▼ | $-13.47M ▼ |
| Q1-2025 | $32.68M ▲ | $26.91M ▲ | $-34K ▲ | $1.18M ▼ | $28.06M ▲ | $26.88M ▲ |
| Q4-2024 | $-15.64M ▼ | $-38.88M ▼ | $-90K ▼ | $1.74M ▲ | $-37.24M ▼ | $-38.97M ▼ |
| Q3-2024 | $88.78M | $-34.68M | $141.14M | $-110.87M | $-4.41M | $-34.81M |
Revenue by Products
| Product | Q3-2018 | Q4-2018 | Q2-2018 | Q4-2019 |
|---|---|---|---|---|
 License And Service | $10.00M ▲ | $10.00M ▲ | $0 ▼ | $10.00M ▲ |
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Thomas J. DesRosier
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-22 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FLAGSHIP VENTURES FUND IV, L.P.
Shares:14.08M
Value:$226.46M
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
Shares:12.68M
Value:$203.94M
BLACKROCK INC.
Shares:1.76M
Value:$28.34M
Summary
Showing Top 3 of 60